- Home
- EP vs SKYE Comparison
EP vs SKYE Comparison
Compare EP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EP
- SKYE
- Stock Information
- Founded
- EP 1983
- SKYE 2012
- Country
- EP United States
- SKYE United States
- Employees
- EP N/A
- SKYE N/A
- Industry
- EP Oil & Gas Production
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- EP Energy
- SKYE Health Care
- Exchange
- EP Nasdaq
- SKYE Nasdaq
- Market Cap
- EP 170.7M
- SKYE 172.9M
- IPO Year
- EP N/A
- SKYE N/A
- Fundamental
- Price
- EP $5.22
- SKYE $5.58
- Analyst Decision
- EP
- SKYE Strong Buy
- Analyst Count
- EP 0
- SKYE 5
- Target Price
- EP N/A
- SKYE $18.40
- AVG Volume (30 Days)
- EP 35.1K
- SKYE 147.7K
- Earning Date
- EP 11-11-2024
- SKYE 11-09-2024
- Dividend Yield
- EP N/A
- SKYE N/A
- EPS Growth
- EP N/A
- SKYE N/A
- EPS
- EP N/A
- SKYE N/A
- Revenue
- EP $42,871,387.00
- SKYE N/A
- Revenue This Year
- EP N/A
- SKYE N/A
- Revenue Next Year
- EP N/A
- SKYE N/A
- P/E Ratio
- EP N/A
- SKYE N/A
- Revenue Growth
- EP N/A
- SKYE N/A
- 52 Week Low
- EP $4.06
- SKYE $1.44
- 52 Week High
- EP $10.99
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- EP 50.88
- SKYE 46.06
- Support Level
- EP $4.50
- SKYE $5.71
- Resistance Level
- EP $5.14
- SKYE $7.11
- Average True Range (ATR)
- EP 0.28
- SKYE 0.56
- MACD
- EP -0.02
- SKYE -0.02
- Stochastic Oscillator
- EP 44.30
- SKYE 0.00
About EP Empire Petroleum Corporation
Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the US onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.